Captor Therapeutics (CTX) investor relations material

Executive summary

• Revenue from R&D services dropped to PLN 1,962k in H1 2026 from PLN 4,616k year-over-year, reflecting lower collaboration activity.

• Net loss widened to PLN 22,762k from PLN 20,474k year-over-year, driven by increased R&D and project costs.

• Share capital increased to 6,353,397 shares due to new share issues, raising PLN 65.6m in March 2026.

• No dividends were paid or proposed during the period.

Financial highlights

• Operating loss increased to PLN 24,189k from PLN 21,461k year-over-year.

• Cash and cash equivalents at period end: PLN 2,403k, down from PLN 10,719k at year-end 2025.

• Net cash outflow from operating activities: PLN -24,628k (vs. inflow of PLN 12,464k in H1 2025, which included share issue proceeds).

• Equity rose to PLN 65,065k from PLN 23,481k at year-end 2025, mainly due to the share issue.

• Grant revenue was PLN 2,262k, mainly for viadrudomide and vratitoclax projects.

Outlook and guidance

• Management expects sufficient financial resources for at least 12 months, supported by the March 2026 share issue and ongoing partnership discussions.

• Advanced talks for partnering agreements on NEK7 degraders and other projects could provide additional funding.

• Further collaborations and grant funding are being pursued to support platform development beyond 2026.